We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-1.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
-$253M
Cap. Flow
-$97.3M
Cap. Flow %
-8.43%
Top 10 Hldgs %
65.98%
Holding
89
New
12
Increased
29
Reduced
25
Closed
19
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1.2 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
1 year

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$63.1M
2
NTRA icon
Natera
NTRA
+$45.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.6M
4
ILMN icon
Illumina
ILMN
+$14.6M
5
MCRB icon
Seres Therapeutics
MCRB
+$9.91M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$67.4M
2
AVTR icon
Avantor
AVTR
+$28M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$21.6M
4
ARGX icon
argenx
ARGX
+$16.9M
5
FATE icon
Fate Therapeutics
FATE
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 72.39%
2 Miscellaneous 27.61%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$482B
$209M 18.11%
781,700
+511,700
+190% +$154M
2021 Q4
3 quarters
BHVN icon
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$96.3M 8.35%
637,139
+4,345
+0.7% +$644K
2021 Q4
3 quarters
GSK icon
3
GSK
GSK
$99.4B
$87.3M 7.56%
2,939,070
+1,663,773
+130% +$63.1M
2018 Q1
18 quarters
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$78.6M 6.81%
1,269,591
+380,008
+43% +$26.6M
2020 Q2
9 quarters
NTRA icon
5
Natera
NTRA
$56.5B
$62.5M 5.41%
1,425,602
+949,947
+200% +$45.2M
2022 Q2
1 quarter
GSK icon
6
CALL
GSK
GSK
$99.4B
$61.6M 5.34%
2,093,700
+850,740
+68% +$32.2M
2020 Q4
7 quarters
UTHR icon
7
United Therapeutics
UTHR
$23.1B
$53.4M 4.63%
255,226
-55,608
-18% -$12.4M
2020 Q2
9 quarters
DHR icon
8
Danaher
DHR
$161B
$42M 3.64%
183,352
-19,303
-10% -$4.73M
2018 Q3
16 quarters
SNY icon
9
Sanofi
SNY
$96.6B
$37.9M 3.28%
996,035
+116,575
+13% +$5.19M
2022 Q2
1 quarter
TEVA icon
10
Teva Pharmaceutical Industries Limited
TEVA
$48.2B
$32.8M 2.84%
4,062,935
-447,767
-10% -$3.96M
2020 Q3
8 quarters
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$1.2B
$29.1M 2.52%
1,211,434
+217,072
+22% +$4.87M
2022 Q2
1 quarter
NVST icon
12
Envista
NVST
$3.74B
$20.8M 1.8%
633,001
-26,093
-4% -$989K
2020 Q4
7 quarters
ILMN icon
13
Illumina
ILMN
$39.4B
$20.4M 1.77%
109,998
+73,745
+203% +$14.6M
2022 Q1
2 quarters
CYH icon
14
Community Health Systems
CYH
$429M
$19M 1.65%
8,841,604
+780,745
+10% +$2.59M
2020 Q4
7 quarters
CLDX icon
15
Celldex Therapeutics
CLDX
$2.24B
$17.6M 1.53%
626,372
+73,984
+13% +$2.27M
2021 Q4
3 quarters
BIIB icon
16
Biogen
BIIB
$34.5B
$16.1M 1.39%
60,144
-41,270
-41% -$8.76M
2021 Q4
3 quarters
ELV icon
17
Elevance Health
ELV
$92.7B
$15M 1.3%
33,040
-9,745
-23% -$4.66M
2020 Q4
7 quarters
CNC icon
18
Centene
CNC
$34.3B
$14.9M 1.29%
191,308
-42,339
-18% -$3.78M
2021 Q1
6 quarters
LNTH icon
19
Lantheus
LNTH
$6.53B
$14.6M 1.26%
206,893
+26,840
+15% +$2.03M
2022 Q2
1 quarter
BIIB icon
20
PUT
Biogen
BIIB
$34.5B
$13.3M 1.16%
+50,000
New +$10.6M
2022 Q3
0 quarters
AMRN icon
21
Amarin Corp
AMRN
$241M
$13M 1.13%
598,137
-66,108
-10% -$1.77M
2018 Q1
18 quarters
ABMD
22
DELISTED
Abiomed Inc
ABMD
$13M 1.13%
52,970
-16,327
-24% -$4.41M
2022 Q2
1 quarter
MCRB icon
23
Seres Therapeutics
MCRB
$25.1M
$12.4M 1.08%
+96,791
New +$9.91M
2022 Q3
0 quarters
HUM icon
24
Humana
HUM
$50.3B
$11.9M 1.04%
24,572
+13,402
+120% +$6.52M
2022 Q2
1 quarter
BIIB icon
25
CALL
Biogen
BIIB
$34.5B
$9.91M 0.86%
+37,100
New +$7.88M
2022 Q3
0 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Eversept Partners held 89 positions worth $1.15B, down 18% from $1.41B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eversept Partners withdrew a net $97.3M in Q3 2022, closing 19 positions and reducing 25 holdings. Its most notable exit was AstraZeneca, an estimated $67.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 70% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Seres Therapeutics worth $12.4M.

  • Eversept Partners's largest Q3 2022 buy was Seres Therapeutics: 96,791 shares worth $12.4M.
  • Eversept Partners added most to GSK in Q3 2022, an estimated $63.1M increase.
  • Eversept Partners's biggest Q3 2022 reduction was Avantor, cutting an estimated $28M.
  • Eversept Partners fully exited AstraZeneca in Q3 2022, selling an estimated $67.4M.
  • Eversept Partners's ten largest holdings make up 66% of its $1.15B portfolio in Q3 2022.
  • Eversept Partners opened 12 new positions and closed 19 in Q3 2022.
  • Eversept Partners's portfolio value fell 18% quarter-over-quarter to $1.15B.

Based on Eversept Partners's 13F filing for Q3 2022, filed 14 Nov 2022.